ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fusco, Stefania Angela, Gronda, Edoardo, Mocini, Edoardo, Lucà, Fabiana, Bisceglia, Irma, De Luca, Leonardo, Caldarola, Pasquale, Cipriani, Manlio, Corda, Marco, De Nardo, Alfredo, Francese, Giuseppina Maura, Napoletano, Cosimo, Navazio, Alessandro, Riccio, Carmine, Roncon, Loris, Tizzani, Emanuele, Nardi, Federico, Urbinati, Stefano, Valente, Serafina, Gulizia, Michele Massimo, Gabrielli, Domenico, Oliva, Fabrizio, Imperoli, Giuseppe, Colivicchi, Furio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Position Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117908/
https://www.ncbi.nlm.nih.gov/pubmed/35602255
http://dx.doi.org/10.1093/eurheartj/suac017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117908/
https://www.ncbi.nlm.nih.gov/pubmed/35602255
http://dx.doi.org/10.1093/eurheartj/suac017

Ejemplares similares